ELVN
Price
$20.74
Change
-$0.63 (-2.95%)
Updated
Jun 6 closing price
Capitalization
1.05B
60 days until earnings call
ERAS
Price
$1.60
Change
+$0.03 (+1.91%)
Updated
Jun 6 closing price
Capitalization
444.76M
60 days until earnings call
Interact to see
Advertisement

ELVN vs ERAS

Header iconELVN vs ERAS Comparison
Open Charts ELVN vs ERASBanner chart's image
Enliven Therapeutics
Price$20.74
Change-$0.63 (-2.95%)
Volume$663.45K
Capitalization1.05B
Erasca
Price$1.60
Change+$0.03 (+1.91%)
Volume$1.73M
Capitalization444.76M
ELVN vs ERAS Comparison Chart
Loading...
ELVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELVN vs. ERAS commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELVN is a Buy and ERAS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (ELVN: $16.07 vs. ERAS: $1.10)
Brand notoriety: ELVN and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELVN: 82% vs. ERAS: 88%
Market capitalization -- ELVN: $1.05B vs. ERAS: $444.76M
ELVN [@Biotechnology] is valued at $1.05B. ERAS’s [@Biotechnology] market capitalization is $444.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELVN’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • ELVN’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both ELVN and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELVN’s TA Score shows that 4 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • ELVN’s TA Score: 4 bullish, 5 bearish.
  • ERAS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than ELVN.

Price Growth

ELVN (@Biotechnology) experienced а -5.08% price change this week, while ERAS (@Biotechnology) price change was -9.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

ELVN is expected to report earnings on Aug 07, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELVN($1.05B) has a higher market cap than ERAS($445M). ELVN YTD gains are higher at: -28.578 vs. ERAS (-56.175). ELVN has higher annual earnings (EBITDA): -104.24M vs. ERAS (-153.28M). ELVN (313M) and ERAS (298M) have equal amount of cash in the bank . ELVN has less debt than ERAS: ELVN (0) vs ERAS (51.9M). ELVN (0) and ERAS (0) have equivalent revenues.
ELVNERASELVN / ERAS
Capitalization1.05B445M236%
EBITDA-104.24M-153.28M68%
Gain YTD-28.578-56.17551%
P/E RatioN/AN/A-
Revenue00-
Total Cash313M298M105%
Total Debt051.9M-
TECHNICAL ANALYSIS
Technical Analysis
ELVNERAS
RSI
ODDS (%)
N/A
Bullish Trend 12 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 12 days ago
87%
Momentum
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
90%
MACD
ODDS (%)
Bearish Trend 12 days ago
88%
Bearish Trend 12 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
89%
Bearish Trend 12 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
87%
Bearish Trend 12 days ago
90%
Advances
ODDS (%)
Bullish Trend 27 days ago
81%
Bullish Trend about 1 month ago
79%
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 18 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 12 days ago
75%
Bullish Trend 12 days ago
86%
Aroon
ODDS (%)
Bullish Trend 12 days ago
82%
Bullish Trend 12 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ELVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

ELVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELVN has been loosely correlated with APGE. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVN jumps, then APGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELVN
1D Price
Change %
ELVN100%
+0.50%
APGE - ELVN
52%
Loosely correlated
-1.30%
ERAS - ELVN
49%
Loosely correlated
+1.85%
BHVN - ELVN
47%
Loosely correlated
-1.83%
DNLI - ELVN
46%
Loosely correlated
-1.29%
COGT - ELVN
46%
Loosely correlated
N/A
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+1.85%
RVMD - ERAS
57%
Loosely correlated
+2.04%
XNCR - ERAS
57%
Loosely correlated
-2.58%
KYMR - ERAS
56%
Loosely correlated
+2.35%
BEAM - ERAS
53%
Loosely correlated
-0.88%
APGE - ERAS
53%
Loosely correlated
-1.30%
More